Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation.
protein | Protein subunit | Protein-protein interaction | Tau Beta Pi | Hfq protein | protein domain | Protein-protein_interaction | Tau | Tau Ceti | Protein Data Bank | Zeta Beta Tau | RNA-binding protein | Bà Rịa–Vũng Tàu Province | Zeta Tau Alpha | Vũng Tàu | Tau Beta Sigma | Sha Tau Kok | Promyelocytic leukemia protein | G protein | Wiskott–Aldrich syndrome protein | Vung Tau | Tau, American Samoa | Protein G | protein dimer | Protein A | Delta Tau Delta | C-reactive protein | Bone morphogenetic protein 2 | AMP-activated protein kinase | Alpha Tau Omega |